This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Despite adequate control of positive symptoms, many patients with schizophrenia suffer from severe cognitive deficits that limit their ability to realize optimal functional capacity. Medications that enhance dopaminergic activity in the prefrontal cortex may be ideal to improve cognition without worsening psychosis. Atomoxetine has been shown in pre-clinical studies to increase dopamine levels in prefrontal cortex but not in subcortical regions such as striatum and nucleus accumbens. Therefore, we believe that it may be extremely useful, when added to a stable regimen of antipsychotic medication, in enhancing cognition in patients with schizophrenia. In the proposed study, we will conduct baseline neurocognitive tests and measure activation of the prefrontal cortex by a working memory test during functional magnetic resonance imaging (fMRI) in patients with schizophrenia and schizoaffective disorder. Patients will then be randomized to receive either atomoxetine or placebo in addition to their regular dose of antipsychotic medication. The starting dose of atomoxetine will be 40 mg per day which will be increased to 40 mg bid after four weeks and then continued at this dose for the next four weeks. After four and eight weeks of treatment, repeat neurocognitive tests will be conducted and the fMRI will be repeated only after eight weeks of treatment.
Showing the most recent 10 out of 869 publications